Linezolid for extensively drug-resistant tuberculosis [1]

New England Journal of Medicine

Volumn 368, Issue 3, 2013, Pages 290-291

  Jaramillo, Ernesto ^a   Weyer, Karin ^a   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; QUINOLONE DERIVATIVE; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SALVAGE THERAPY; DRUG MISUSE; INFECTION RISK; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS; FEMALE; MALE; NOTE;

ACETAMIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; OXAZOLIDINONES;

EID: 84872451497     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1214183     Document Type: Letter

References (4)

1. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006 (WHO/HTM/TB/2006.361).
2. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva: World Health Organization, 2011 (WHO/HTM/TB/2011.6).
3. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
4. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17. [Erratum, Lancet 2012;380:1386.]